ADMET

Fierce Medtech Names Genesis Therapeutics a “Fierce 15” Company of 2023

Retrieved on: 
Wednesday, March 6, 2024
Technology, Biotechnology, Health, Other Health, Pharmaceutical, Artificial Intelligence, Other Science, Other Technology, Research, Software, General Health, Health Technology, Science, Data Management, Therapy, ADMET, GEMS, AI, Medtech, Drug discovery, Patient, Pharmaceutical industry

Genesis Therapeutics , a company pioneering generative and predictive artificial intelligence (AI) technologies to develop breakthrough therapeutics for underserved patient populations, today announced that Fierce Medtech has named it as one of 2023’s “Fierce 15” medtech companies.

Key Points: 
  • Genesis Therapeutics , a company pioneering generative and predictive artificial intelligence (AI) technologies to develop breakthrough therapeutics for underserved patient populations, today announced that Fierce Medtech has named it as one of 2023’s “Fierce 15” medtech companies.
  • "We are honored to receive this recognition from Fierce and be included among true innovators in AI and life sciences," said Evan Feinberg, Ph.D., co-founder and CEO of Genesis.
  • Being named a Fierce 15 company is testament that our team is yielding tangible results in developing AI technologies that generate transformative drugs for patients."
  • “These companies exemplify the ability of the life sciences industry to turn cutting-edge ideas into meaningful outcomes.”

Eurofins Discovery Introduces Innovative DiscoveryAI SAFIRE: A New AI-Driven Platform for Drug Discovery Trained Using Proprietary Datasets

Retrieved on: 
Thursday, February 29, 2024
Health Technology, Data Management, Other Health, Technology, Pharmaceutical, Apps, Applications, Biometrics, Medical Devices, Artificial Intelligence, Other Technology, Biotechnology, Science, Software, Other Science, Research, Health, ADMET, Artificial intelligence, ADME, Machine learning, Phi coefficient, Absorption, Drug discovery, Metabolism, Suite

Eurofins Discovery , an industry-leading provider of products and services for drug discovery research, today announced the launch of DiscoveryAI SAFIRE (Suite of ADMET Predictions For In Silico Refinement and Evaluation).

Key Points: 
  • Eurofins Discovery , an industry-leading provider of products and services for drug discovery research, today announced the launch of DiscoveryAI SAFIRE (Suite of ADMET Predictions For In Silico Refinement and Evaluation).
  • SAFIRE is an advanced platform that leverages proprietary datasets, artificial intelligence (AI), and machine learning (ML), offering a unique capability for expediting discovery.
  • It’s proven effective in accelerating drug discovery projects from initial hit discovery through to lead optimization.
  • For more details about SAFIRE’s benefits and significant value to the drug discovery community, visit eurofinsdiscovery.com/safire .

Simulations Plus Extends Collaboration with Major Toxicology Research Agency

Retrieved on: 
Thursday, February 15, 2024
Health, Technology, Software, Research, Science, Pharmaceutical, Biotechnology, SLP, Environ, Division, Metabolism, Toxicology, Toxicity, North American Menopause Society, Absorption, Biopharmaceutical, Animal, NIEHS, Skin, Risk, Vivo, ADMET, Safety, DTT, Computation, Cheminformatics, Environmental health, Pharmacokinetics, Simulations Plus, Child, Machine learning, Human, Environment, Pharmaceutical industry

“At NIEHS, we seek to expand scientific knowledge and approach methods linking the environment and human health.

Key Points: 
  • “At NIEHS, we seek to expand scientific knowledge and approach methods linking the environment and human health.
  • “Importantly, these tools are being investigated for their potential to address a critical gap in toxicology research for understanding and modeling human bioactivation of environmental chemicals through xenobiotic metabolism,” Ferguson added.
  • Principal Scientist in the Cheminformatics Solutions team at Simulations Plus.
  • It is the leading physiologically based pharmacokinetic/physiologically based biopharmaceutics modeling (PBPK/PBBM) platform, built and refined over 25 years on the most up-to-date scientific research.

Anima Biotech Announces Preclinical Data of Candidate in Idiopathic Pulmonary Fibrosis

Retrieved on: 
Wednesday, February 7, 2024
Extracellular matrix, Tech, Cell, Eli Lilly, AI, Phenotype, Biomarker, Patient, Fibroblast, Idiopathic pulmonary fibrosis, Drug discovery, Messenger, Myofibroblast, AbbVie, Disease, IPF, ADMET, Pharmaceutical industry

BERNARDSVILLE, N.J., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Anima Biotech, the Tech.Bio leader bringing AI to mRNA biology, announced today positive preclinical data of its lung fibrosis candidate.

Key Points: 
  • BERNARDSVILLE, N.J., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Anima Biotech, the Tech.Bio leader bringing AI to mRNA biology, announced today positive preclinical data of its lung fibrosis candidate.
  • This drug operates through a novel mRNA biology mechanism of action, opening new avenues for treating Idiopathic Pulmonary Fibrosis (IPF) patients.
  • Utilizing its mRNA Lightning™ Platform, Anima has successfully identified a preclinical candidate operating through a novel mRNA biology mechanism of action, effectively disrupting the transformation of fibroblasts into fully differentiated myofibroblasts.
  • By inhibiting myofibroblasts' deposition of extracellular matrix, this candidate demonstrates substantial potential in mitigating fibrotic diseases.

Simulations Plus Releases GastroPlus® Version 9.9

Retrieved on: 
Tuesday, January 30, 2024
Biotechnology, Pharmaceutical, Public Relations, Investor Relations, Health, FDA, Communications, Chemicals, Plastics, Manufacturing, Simulations Plus, Research, Patient, Safety, ADMET, SLP, ADR, Human

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced the release of GastroPlus® 9.9, the latest version of its flagship physiologically based pharmacokinetics/biopharmaceutics (PBPK/PBBM) modeling and simulation software.

Key Points: 
  • Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced the release of GastroPlus® 9.9, the latest version of its flagship physiologically based pharmacokinetics/biopharmaceutics (PBPK/PBBM) modeling and simulation software.
  • Upgraded with ADMET Predictor® version 11 models, enhancing our First in Human Simulator
    “Our software updates reflect the needs our customers communicate to us, and GastroPlus 9.9 is no exception,” said Neil Miller , Vice President of Simulation Sciences at Simulations Plus.
  • “We incorporated feedback from more than 100 companies into these latest enhancements, ensuring they truly provide the improved functionality our customers require.
  • “This is one reason our clients know they can rely on data generated with GastroPlus to inform their program design and support regulatory submissions.

Schrödinger Provides Update on Progress Across the Business and Outlines 2024 Development and Operational Goals

Retrieved on: 
Monday, January 8, 2024
Health, Technology, Software, Research, Science, Pharmaceutical, Biotechnology, PKA, Lilly, Drug discovery, Lymphoid leukemia, ADMET, IND, CDC7, MDS, Eli Lilly and Company, MBBS, NLRP3, MALT1, Webcast, Patient, Therapy, AML, Pharmaceutical industry

Schrödinger , Inc. (Nasdaq: SDGR), Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today provided an update on its progress across the business and announced its development and operational goals for 2024.

Key Points: 
  • Schrödinger , Inc. (Nasdaq: SDGR), Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today provided an update on its progress across the business and announced its development and operational goals for 2024.
  • Today Schrödinger announced an expanded, three-year, software agreement with Eli Lilly and Company.
  • The three-year agreement builds on the collaboration established in 2022.
  • Schrödinger will provide advanced support to ensure full integration and optimization of the platform across Lilly’s research sites.

Inductive Bio Emerges from Stealth, Unveiling an ML Platform to Accelerate Compound Optimization in Drug Discovery

Retrieved on: 
Wednesday, December 13, 2023
Meetup, Character, Lux Capital, ADMET, Therapy, QSAR, Data, Patient, Algorithm, Atlas Venture, Machine learning, Absorption, Flatiron, Drug discovery, Hand, Roche, Pain, ADME, Atlas, Metabolism, SVP, Genentech, Pharmaceutical industry, Induction, Venture, Toxicity

NEW YORK, Dec. 13, 2023 /PRNewswire/ -- Inductive Bio, a technology company developing a machine learning (ML) platform designed to dramatically accelerate the compound optimization process, emerged from stealth today with $4.3M in funding.

Key Points: 
  • NEW YORK, Dec. 13, 2023 /PRNewswire/ -- Inductive Bio, a technology company developing a machine learning (ML) platform designed to dramatically accelerate the compound optimization process, emerged from stealth today with $4.3M in funding.
  • Their seed round was co-led by Andreessen Horowitz (a16z) Bio + Health and Lux Capital, with participation from Character, Bessemer Venture Partners, Alleycorp, and others.
  • Inductive Bio was co-founded by Josh Haimson and Ben Birnbaum who had previously built out the ML organization at Flatiron Health, which was acquired by Roche in 2018.
  • Denali has integrated custom ADME models from Inductive into their small molecule drug design platform to support rapid, data-driven decision making.

Schrödinger Reports Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, November 1, 2023
Software, Biotechnology, Pharmaceutical, Oncology, General Health, Health, Technology, Clinical Trials, United European Gastroenterology, PH, PRMT5, Trial of the century, Global health, IND, Acute myeloid leukemia, MALT1, Food, PKA, FEP, Myelodysplastic syndrome, Regulation of tobacco by the U.S. Food and Drug Administration, GAAP, Mantle cell lymphoma, Research, Bill, Ulcerative colitis, Bill & Melinda Gates Foundation, Pharmacokinetics, CDC7, Phases of clinical research, Webcast, ADMET, UEG, Safety, Overweight, Therapy, Investment, Table, Patient, Cryptocurrency, Pharmaceutical industry, Bank, EU

Schrödinger today updated its financial guidance for 2023.

Key Points: 
  • Schrödinger today updated its financial guidance for 2023.
  • The Phase 1 dose-escalation study in healthy volunteers is nearing completion, and the company expects to report data from the study in the fourth quarter of 2023.
  • Schrödinger will host a conference call to discuss its third quarter 2023 financial results on Wednesday, November 1, 2023, at 4:30 p.m.
  • Schrödinger will host its Pipeline Day in New York City on Thursday, December 14, 2023, beginning at 10:00 a.m.

Rockland Launches Novel Analytical Tools to Assess Drug Delivery: Revolutionizing Oligonucleotide Therapeutic Development

Retrieved on: 
Tuesday, October 17, 2023
Triage, IHC, Drug development, RNA, Cell, DNA-binding protein, ELISA, In situ hybridization, ADMET, Panel, Absorption, Metabolism, ISH, Collection, MOE, Toxicology, PS, ASO, Small RNA, Ome, Tissue, Immunohistochemistry, Messenger, Serum, Vaccine, Fine chemical

LIMERICK, Pa., Oct. 17, 2023 /PRNewswire/ -- Rockland is a leading USA-based life science company, developing analytical tools that assist in the collection of pharmacodynamic, pharmacokinetic, and toxicology data critical for satisfying regulatory requirements for biological drugs, cell and gene therapies, and RNA therapeutic drugs (e.g., ASO, siRNA, mRNA). To date, Rockland has successfully generated reagents against many diverse nucleic acid chemical structures and modifications, including conventional oligonucleotides, DNA-RNA hybrids, single- and double-stranded RNA, and more.

Key Points: 
  • To date, Rockland has successfully generated reagents against many diverse nucleic acid chemical structures and modifications, including conventional oligonucleotides, DNA-RNA hybrids, single- and double-stranded RNA, and more.
  • Traditionally, ISH-type assays have been the mainstay method of detecting and localizing oligonucleotides in cells and tissues for nucleic acid therapy development.
  • Introducing the ModDetect™ Phosphorothioate (PS) Panel, an immunoassay-based alternative that provides robust detection of oligonucleotide therapeutic drug delivery and analysis, facilitating the collection of ADMET analytical data for regulatory approval.
  • ModDetect ™ is a growing suite of analytical tools generated against different types of nucleic acid chemical modifications.

Genesis Therapeutics Closes Oversubscribed $200 Million Series B

Retrieved on: 
Monday, August 21, 2023
Biotechnology, Technology, Health, Pharmaceutical, Health Technology, Other Science, Research, Software, Artificial Intelligence, Science, Clinical Trials, GEMS, SAFE, Stanford University, Deep learning, BlackRock, Genentech, Eli Lilly, Patient, Structural biology, ADMET, Menlo Ventures, Artificial intelligence, Therapy, Computer science, Genesis, Pharmaceutical industry, Medical device, Chemistry, Series

Genesis Therapeutics , a company pioneering artificial intelligence (AI) technologies to create breakthrough medicines for patients with severe diseases, announced today that it has closed an oversubscribed $200 million round of Series B financing.

Key Points: 
  • Genesis Therapeutics , a company pioneering artificial intelligence (AI) technologies to create breakthrough medicines for patients with severe diseases, announced today that it has closed an oversubscribed $200 million round of Series B financing.
  • Additionally, the Series B capital will enable Genesis to ambitiously expand its pipeline, initiating new programs for underserved patient populations and leveraging the GEMS platform to make progress against challenging and previously undruggable targets.
  • This funding brings the total capital raised by Genesis Therapeutics to over $280 million.
  • In addition to the $200 million Series B raise, Genesis further announced that approximately $24 million of SAFE notes from a prior financing round, led by Radical Ventures, converted alongside the close of the Series B. Genesis previously raised a $52 million Series A , led by Rock Springs Capital, and a seed round of $4 million, led by a16z Bio + Health.